BioSpace News Archive

Unveils development strategy for lanraplenib (LANRA), which will expand addressable patient population for SYK inhibitor portfolio in acute myeloid leukemia (AML); plans to initiate two Phase 1/2 trials in late 2021 and early 2022

PharmaTher Holdings Ltd., a clinical-stage psychedelics biotech company, is pleased to announce that it has filed an application with the U.S. Food and Drug Administration to receive Orphan Drug Designation for ketamine to treat amyotrophic lateral sclerosis, also known as Lou Gehrig’s disease.

AbbVie announced that the European Commission has approved VENCLYXTO® in combination with a hypomethylating agent, azacitidine or decitabine, for the treatment of adult patients with newly diagnosed acute myeloid leukemia who are ineligible for intensive chemotherapy.1 The approval is valid in all 27 member states of the EU, as well as Iceland, Liechtenstein, and Norway.

The award from CDMRP will help fund the investigational new drug enabling toxicology studies for the company’s PIKFYVE-targeting drug candidate for ALS

Breadth of data presented demonstrates AbbVie’s longstanding commitment to develop a portfolio of solutions that advance standards of care for people living with rheumatic diseases

Eclipse Bioinnovations, a leading RNA genomics company offering technology solutions that accelerate RNA research, will be presenting four scientific posters and a webinar at the RNA Society 2021 annual meeting to be held virtually May 25 through June 4, 2021.

Tavanta Therapeutics, a specialty pharmaceutical company, announced that the first patient has been dosed in a recently initiated global Phase 3 clinical trial evaluating TAVT-45 Granules for oral suspension, a novel and proprietary formulation of abiraterone acetate.

Agreement aims to accelerate development of a unique testosterone treatment for inflammatory breast diseases and estrogen-receptor positive breast cancer

Ardelyx, Inc., a biopharmaceutical company focused on developing innovative first-in-class medicines to improve treatment for people with kidney and cardiorenal diseases, announced that Mike Raab, president and chief executive officer of Ardelyx, will participate in a fireside chat at the Jefferies Virtual Healthcare Conference on Tuesday, June 1, 2021 at 3:30 p.m. ET.

ARTMS Inc. is pleased to announce the production of Ga-68 Chloride using a medical cyclotron in a US based commercial nuclear pharmacy.